Literature DB >> 35673336

Lipoprotein(a) is Associated with Cardiovascular Events in Low Risk Males: Results from a Health Checkup Cohort with Long-Term Follow-Up.

Yi-Chun Huang1, Yu-Wen Cheng1, Victor Chien-Chia Wu1, Chia-Pin Lin1, Yi-Wei Kao2, Pao-Hsien Chu1,3, Yu-Sheng Lin1,3,4.   

Abstract

Objective: Elevated lipoprotein(a) level is an independent risk factor for atherosclerotic cardiovascular disease. However, the strength of this association in healthy individuals is unknown.
Methods: In this retrospective cohort study, we reviewed medical records obtained from a Health Examination Program. The records, covering the period 2002-2015, were from 2,634 men at low risk, as indicated by their Framingham Risk Score and Systematic Coronary Risk Evaluation (SCORE) score, and included lipoprotein(a) data. We categorized the participants on the basis of their lipoprotein(a) level and analyzed the association of this level with cardiovascular events.
Results: The study population had a mean age of 46 years. In total, 32 cardiovascular disease events - 6 strokes and 26 coronary artery events - were identified. An increase of 5 mg/dL in the lipoprotein(a) level (independent of low-density cholesterol) raised the cardiovascular disease risk by 8% over a period of 10 years (p = 0.014). Sensitivity analysis also yielded this result, even after excluding hypertension and diabetes. Conclusions: Elevated lipoprotein(a) may be a risk factor for coronary artery disease, even in male populations defined as having a low risk according to the Framingham Risk Score and SCORE.

Entities:  

Keywords:  Cardiovascular risk; Lipid; Lipoprotein(a); Myocardial infarction

Year:  2022        PMID: 35673336      PMCID: PMC9121757          DOI: 10.6515/ACS.202205_38(3).20211225A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   1.800


  28 in total

1.  Low bone mineral density may be associated with long-term risk of cancer in the middle-aged population: A retrospective observational study from a single center.

Authors:  Hsin-Fu Lee; Chiao-En Wu; Yu-Sheng Lin; Jaw-Shan Hwang; Chu-Hua Wu; Pao-Hsien Chu
Journal:  J Formos Med Assoc       Date:  2017-05-16       Impact factor: 3.282

2.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  J Am Coll Cardiol       Date:  2018-11-10       Impact factor: 24.094

3.  Ultrasound scanning in the detection of hepatic fibrosis and steatosis.

Authors:  S H Saverymuttu; A E Joseph; J D Maxwell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

Review 4.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

5.  The Optimal Cut-off Value of Plasma BNP to Differentiate Heart Failure in the Emergency Department in Japanese Patients with Dyspnea.

Authors:  Kotaro Nakata; Kimiaki Komukai; Yutaka Yoshii; Satoru Miyanaga; Takeyuki Kubota; Tsuneharu Kosuga; Kenichiro Suzuki; Takayuki Yamada; Jun Yoshida; Haruka Kimura; Masamichi Takagi; Mitsuyuki Shimizu; Michihiro Yoshimura
Journal:  Intern Med       Date:  2015-12-01       Impact factor: 1.271

6.  Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Authors:  Peter Willeit; Paul M Ridker; Paul J Nestel; John Simes; Andrew M Tonkin; Terje R Pedersen; Gregory G Schwartz; Anders G Olsson; Helen M Colhoun; Florian Kronenberg; Christiane Drechsler; Christoph Wanner; Samia Mora; Anastasia Lesogor; Sotirios Tsimikas
Journal:  Lancet       Date:  2018-10-04       Impact factor: 79.321

7.  Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.

Authors:  Pia R Kamstrup; Marianne Benn; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

8.  Lipoprotein(a) as a cardiovascular risk factor: current status.

Authors:  Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2010-10-21       Impact factor: 29.983

9.  Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study.

Authors:  Yook Chin Chia; Sarah Yu Weng Gray; Siew Mooi Ching; Hooi Min Lim; Karuthan Chinna
Journal:  BMJ Open       Date:  2015-05-19       Impact factor: 2.692

10.  Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study.

Authors:  Li-Wei Chen; Cheng-Hung Chien; Sheng-Fong Kuo; Chia-Ying Yu; Chih-Lang Lin; Rong-Nan Chien
Journal:  BMC Gastroenterol       Date:  2019-07-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.